Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

Magainin-2vsThymalin

Amphipathic 23-amino-acid antimicrobial peptide from Xenopus laevis skin — the founding member of the magainin family discovered by Michael Zasloff at NIH in 1987, operating through the toroidal pore membrane disruption model with broad-spectrum activity against Gram-positive and Gram-negative bacteria, whose synthetic derivative Pexiganan (MSI-78) advanced to Phase III clinical trials for diabetic foot ulcers

Russian thymic peptide complex that rejuvenates immune function and supports healthy aging

ImmuneImmune

At a Glance

Quick
comparison

Dose Range

Magainin-2

1–5 mg

Thymalin

5–10 mg

Frequency

Magainin-2

Multiple times daily

Thymalin

Once daily

Administration

Magainin-2

Topical application (primary clinical route)

Thymalin

Intramuscular injection

Cycle Length

Magainin-2

4-6 weeks

Thymalin

4-6 weeks

Onset Speed

Magainin-2

Rapid (hours to days)

Thymalin

Moderate (1-2 weeks)

Evidence Level

Magainin-2

Moderate human trials (Phase 1-2)

Thymalin

Limited human trials

Efficacy

Benefit
ratings

Magainin-2
Thymalin

Healing

Magainin-292%
Thymalin0%

Immune

Magainin-285%
Thymalin0%

Immune Restoration

Magainin-20%
Thymalin88%

Longevity Support

Magainin-20%
Thymalin82%

Disease Prevention

Magainin-20%
Thymalin78%

Technical Data

Compound
specifications

Magainin-2

Molecular Formula

C114H180N30O29S

Molecular Weight

2,466.9 g/mol (magainin-2); Pexiganan (MSI-78): ~2,500 Da

Half-Life

Plasma half-life: minutes (rapid proteolytic degradation by serum proteases); local tissue persistence in wound environment: hours at therapeutic concentrations

Bioavailability

Topical bioavailability: local tissue concentrations achieve bactericidal levels with 1-2% cream formulation; systemic bioavailability minimal — rapidly degraded by tissue proteases if absorbed; poor oral bioavailability

CAS Number

108433-95-0

Thymalin

Molecular Formula

Complex mixture; active dipeptide EW: C16H19N3O5

Molecular Weight

Polypeptide complex; components 250-1000 Da; active dipeptide EW ~321 Da

Half-Life

Not precisely characterized for complex; immune effects persist weeks post-administration

Bioavailability

High via intramuscular or subcutaneous injection

CAS Number

63958-90-7

Protocols

Dosing
tiers

Magainin-2

starting

0.5-1% topical cream or 1-2 mg in research solution

Once daily

3-5 days initial evaluation

Begin with low-concentration topical formulation for initial tolerability assessment. Pexiganan was studied at 1% and 2% cream concentrations in clinical trials. Apply thin layer to clean wound bed or infection site. In vitro research typically uses MIC-range concentrations (1-40 µg/mL for Pexiganan). Monitor for local irritation. This is an investigational compound — use under research supervision.

standard

1% topical cream (10 mg/g) or 2-3 mg in research solution

Twice daily

7-14 days

Standard clinical concentration from Phase III trials. Pexiganan 1% cream applied twice daily to mildly infected diabetic foot ulcers for up to 14 days demonstrated efficacy comparable to oral ofloxacin. Ensure wound bed is clean and debrided before application. Cover with non-adherent wound dressing. Monitor wound healing progress and signs of infection resolution.

advanced

2% topical cream (20 mg/g) or 5 mg in research solution

Twice daily

14-28 days

Higher concentration for recalcitrant wound infections or biofilm-involved infections. Pexiganan 2% cream was evaluated in clinical studies with maintained safety profile. Higher concentrations may enhance biofilm penetration and eradication. Extended treatment for chronic wounds. Monitor for increased local irritation. Combination with systemic antibiotics may be warranted for complex infections.

Thymalin

starting

5 mg daily

Once daily

5 days

Initial dose to assess tolerance and immune response; best for first-time users

standard

10 mg daily

Once daily

10 days

Standard clinical protocol used in most Russian research studies; most effective dose

advanced

10 mg Thymalin + 5 mg Epitalon daily

Once daily

20 days, repeated every 6 months

Combined peptide protocol for enhanced longevity and geroprotective effects

Applications

Best
suited for

Magainin-2

Research into topical antimicrobial peptides for diabetic foot ulcer management

Magainin-2 is particularly well-suited for individuals focused on research into topical antimicrobial peptides for diabetic foot ulcer management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Understanding the toroidal pore model of antimicrobial peptide membrane disruption

Magainin-2 is particularly well-suited for individuals focused on understanding the toroidal pore model of antimicrobial peptide membrane disruption. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Development of resistance-proof antimicrobial agents targeting membrane architecture

Magainin-2 is particularly well-suited for individuals focused on development of resistance-proof antimicrobial agents targeting membrane architecture. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Investigation of selective anticancer activity mediated by membrane phospholipid asymmetry

Magainin-2 is particularly well-suited for individuals focused on investigation of selective anticancer activity mediated by membrane phospholipid asymmetry. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymalin

Aging Adults Seeking Immune Support

Thymalin is especially valuable for people over 55 whose thymus gland has naturally shrunk with age. By stimulating thymic function, it helps restore the immune training center that your body relies on to fight infections and stay healthy.

Longevity and Anti-Aging Protocols

Clinical studies tracking patients for 6-8 years showed Thymalin reduced mortality by 2.0-2.1-fold. Combined with Epitalon, the mortality reduction reached an impressive 4.1-fold, making this combination one of the most studied longevity peptide protocols.

Seasonal Illness Prevention

Research shows Thymalin cuts respiratory infection rates by 2.0-2.4-fold. A short 10-day course before cold and flu season can significantly boost your immune defenses for months afterward.

Safety Profile

Side
effects

Magainin-2

Common

  • Application site burning/stinging
  • Local erythema
  • Mild pruritus
  • Increased wound exudate

Uncommon

  • Contact sensitization

Serious

  • No serious systemic adverse effects documented

Thymalin

Common

  • No side effects in most patients
  • Mild injection site reaction

Uncommon

  • Transient low-grade fever
  • Mild flu-like symptoms
  • Temporary headache

Serious

  • Severe allergic reaction

Research Status

Safety
& evidence

Magainin-2

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Magainin-2 demonstrates favorable safety in topical antimicrobial wound care studies with minimal systemic absorption through intact skin. Local tissue irritation minimal at therapeutic concentrations (0.1-1% w/w); hemolytic activity negligible at concentrations <10 μM. No serious adverse events in Phase II wound healing trials. Peptide stability dependent on formulation pH; activity preserved at physiologic pH. Resistance development slower than traditional antibiotics.

Contraindications

  • xKnown hypersensitivity to magainin peptides or amphibian-derived proteins
  • xPregnancy and breastfeeding — insufficient safety data for magainin-derived therapeutics
  • xDeep tissue infections requiring systemic antimicrobial therapy — topical magainin has limited tissue penetration depth
  • xSevere peripheral vascular disease with non-viable tissue — antimicrobial peptides require viable tissue interface for effective action

Thymalin

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Thymalin has an excellent safety profile based on over 40 years of clinical use in Russia. Most patients experience zero side effects, and the peptide complex has been described as 'practically non-toxic' in research literature. It has been used safely in thousands of patients, including elderly populations over extended periods.

Contraindications

  • xActive thymic tumors or malignancies
  • xKnown hypersensitivity to animal-derived peptide products
  • xPregnancy and breastfeeding (insufficient safety data)
  • xSevere uncontrolled autoimmune disease without medical supervision

Decision Guide

Which is
right for you?

Choose Magainin-2 if...

  • Research into topical antimicrobial peptides for diabetic foot ulcer management
  • Understanding the toroidal pore model of antimicrobial peptide membrane disruption
  • Development of resistance-proof antimicrobial agents targeting membrane architecture
  • Investigation of selective anticancer activity mediated by membrane phospholipid asymmetry

Choose Thymalin if...

  • Immune system restoration in aging adults
  • Longevity and healthy aging support
  • Reducing infection frequency and severity
  • Multi-system health optimization